79896-97-2

Basic information

• Product Name: N6-Benzoylarabinoadenosine
• Synonyms: N6-Benzoylarabinoadenosine
• CAS NO: 79896-97-2
• Molecular Formula: C17H17N5O5
• Molecular Weight: 371.352
• Mol File: 79896-97-2.mol
• Article Data: 19

Chemical Properties

• CAS DataBase Reference: N6-Benzoylarabinoadenosine(CAS DataBase Reference)
• NIST Chemistry Reference: N6-Benzoylarabinoadenosine(79896-97-2)
• EPA Substance Registry System: N6-Benzoylarabinoadenosine(79896-97-2)

Safety Data

• Hazardous Substances Data: 79896-97-2(Hazardous Substances Data)

Usage

Description

N6-Benzoylarabinoadenosine is a chemical compound that is composed of a benzoyl group attached to the N6 position of the adenosine molecule. It is a modified form of adenosine and belongs to the family of nucleoside analogs. It possesses potential anti-tumor and anti-viral properties, as well as the ability to inhibit protein synthesis in certain cells. Its unique structure allows it to be a promising candidate for various applications in pharmacology and medicine.

Uses

Used in Pharmaceutical Industry:
N6-Benzoylarabinoadenosine is used as a potential anti-tumor agent for its ability to inhibit protein synthesis in certain cells, making it a candidate for the development of novel cancer therapies.
Used in Antiviral Applications:
N6-Benzoylarabinoadenosine is used as a potential anti-viral agent due to its ability to interfere with viral replication processes, offering a new approach to antiviral therapy.
Used in Gene Therapy:
N6-Benzoylarabinoadenosine is used as a component in gene therapy research, where it may contribute to the development of treatments for genetic disorders by modulating cellular processes at the molecular level.
Used in Research:
N6-Benzoylarabinoadenosine is used as a research tool for studying adenosine receptors and cellular signaling pathways, aiding in the understanding of various biological processes and the development of targeted therapies.

Upstream product

• 98-88-4 benzoyl chloride 
• 5536-17-4 arabinosyl adenine 
• 6984-53-8 C₃₈H₂₉N₅O₈ 
• 63248-73-7 9-((2R,3S,4R,5R)-3,4-Bis-trimethylsilanyloxy-5-trimethylsilanyloxymethyl-tetrahydro-furan-2-yl)-9H-purin-6-ylamine 
• 1336-21-6 ammonium hydroxide 
• 75-77-4 chloro-trimethyl-silane 

Downstream Products

• 77244-83-8 6-N-benzoyl-9-(5-O-tert-butyldiphenylsilyl-β-D-ribofuranosyl)adenine 
• 136834-18-9 N⁶-benzoyl-9-(3,5-di-O-tetrahydropyran-2-yl-β-D-arabinofuranosyl)adenine 
• 115363-48-9 N⁶-benzoyl-5'-O-(monomethoxytrityl)arabinoadenosine 2',3'-bis-O-(methyl N,N-diisopropylphosphoramidite) 
• 115363-49-0 N⁶-benzoyl-5'-O-(monomethoxytrityl)arabinoadenosine 3'-O-(methyl N,N-diisopropylphosphoramidite) 
• 82144-96-5 5'-O-dimethoxytrityl-N,2'-O-dibenzoylarabinosyladenine 
• 82144-95-4 Benzoic acid (2R,3R,4S,5R)-5-(6-benzoylamino-purin-9-yl)-4-[(4-methoxy-phenyl)-diphenyl-methoxy]-2-[(4-methoxy-phenyl)-diphenyl-methoxymethyl]-tetrahydro-furan-3-yl ester 
• 82144-94-3 N,2'-O-dibenzoyl-3',5'-O-bis-monomethoxytrityl arabinosyladenine 
• 93488-74-5 Benzoic acid (2R,3S,4R,5R)-2-(6-benzoylamino-purin-9-yl)-4-hydroxy-5-hydroxymethyl-tetrahydro-furan-3-yl ester 
• 136834-22-5 N-[9-[(2R,3R,4R,5R)-5-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-4-[2-cyanoethoxy-(diisopropylamino)phosphanyl]oxy-3-fluoro-tetrahydrofuran-2-yl]purin-6-yl]benzamide 
• 136834-19-0 N⁶-benzoyl-9-<2-O-(trifluoromethylsulfonyl)-3,5-di-O-tetrahydropyran-2-yl-β-D-arabinofuranosyl>adenine 
• 136834-21-4 N-(9-((2R,3R,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)3-fluoro-4-hydroxytetrahydrofuran-2-yl)9H-purin-6yl)benzamide triethylammonium salt 
• 146954-64-5 N⁶-benzoyl-2'-deoxy-2'-fluoro-3',5'-di-O-tetrahydropyran-2-yladenosine 
• 136834-20-3 N-(9-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-yl)benzamide 
• 20187-82-0 2'-fluorodeoxyadenosine 

Relevant articles and documents

SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS

The present invention relates to synthesis, purification and methods to obtain high purity novel 2'-arabino-O-methyl nucleosides and the corresponding phosphoramidites of various arabinonucleoside bases and introduction of such units into defined sequence

ANTISENSE MODULATION OF EDG1 EXPRESSION

Antisense compounds, compositions and methods are provided for modulating the expression of EDG1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding EDG1. Methods of using these compounds for modulation of EDG1 expression and for treatment of diseases associated with expression of EDG1 are provided.

ANTISENSE MODULATION OF ENDOTHELIAL LIPASE EXPRESSION

Antisense compounds, compositions and methods are provided for modulating the expression of Endothelial Lipase (EL). The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding EL. Methods of using these compounds for modulation of EL expression and for treatment of diseases associated with expression of EL are provided.